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Objective: To evaluate the transgenerational transmission of small for gestational age. 
Methods: Cohort study including a random sample of 2,043 offspring of deliveries 
occurring from 1975 to 1993. Of 623 offspring –now adults- that agreed to participate, 
152 adults (72 born small-for-gestational age (SGA) and 80 with appropriate 
intrauterine growth) reported to have at least one child. Multiple regression analysis was 
used to determine the presence of SGA (defined as a birthweight < 10
th
 percentile) or 
placental mediated disease (defined as the presence of SGA, preeclampsia or gestational 
hypertension) in the following generation. 
Results: Descendants from SGA adults presented lower birthweight percentile (median 
26 [interquartile range 7-52] vs. 43 [19-75]; p<0.001) and higher prevalence of SGA 
(40.3% vs. 16.3%; p=0.001) and placental mediated disease (43.1% vs. 17.5%; 
p=0.001). After adjustment for confounder variables, parental SGA background was 
associated with an almost three-fold increased risk of subsequent SGA or any placental 
mediated disease in the following generation. This association was stronger in SGA 
mothers as compared to fathers. 
Conclusions: Our data provides evidence suggesting a transgenerational transmission of 
SGA highlighting the importance of public health strategies for preventing intrauterine 



















Fetal growth restriction is defined as a failure to reach the growth potential of an 
individual and is considered as a placental-mediated disease that commonly associates 
maternal hypertension/preeclampsia.
1
 It is usually diagnosed as small-for-gestational 
age (SGA) by birth weight below the 10
th
 centile for gestational age.
2
 It affects about 5 
– 10 % of all pregnancies, and is one of the main causes of perinatal morbidity and 
mortality worldwide.
3
 Apart from perinatal complications, individuals born small 




Experimental and human studies also suggest not only effects on the born-small 
individual but also transmission on the subsequent generation,
9–12
 mainly recurrence of 
low birth weight and preeclampsia in offspring of SGA individuals.
13,14
 A 
transgenerational transmission is defined when the latter generations -not exposed to an 
adverse intrauterine condition- develop the same phenotype of their ancestors without a 
genetic inheritance. Interestingly, this transmission is supposed to be mediated by 
epigenetic changes, mainly DNA-methylation, that modulate DNA expression in order 
to better adapt to environment.
15
 Although most of studies have been focused on 
transgenerational effect of low birth weight on the first generation of offspring, there is 
increasing evidence from animal research suggesting that this programmed phenomena 
can be also present in later generations.
15
 Most studies in humans are based on north 
European or American populations born before the 80s and use birth weight –not 
centile- as a surrogate of intrauterine growth.
14,16,17
 
In the present study, we aimed to assess the transgenerational transmission of 
SGA –defined by birth weight centile- in a contemporary Mediterranean population 
with relatively lower prevalence of placental mediated diseases. We used a well-
phenotyped modern population to assess the transmission of SGA and placental 










mediated diseases into first/subsequent offspring taking into account also paternal 
gender.  
  











Study design and patient´s selection 
A cohort study including a random sample of offspring (Generation 1, G1) from 
2,043 deliveries occurring from 1975 to 1993 at Hospital Sant Joan de Déu in Barcelona 
(Figure 1). Delivery books and maternal medical files were reviewed to obtain maternal 
characteristics of generation 0 (G0) and pregnancy outcomes including the diagnosis of 
SGA in the offspring’s (G1) defined as birth weight below the 10
th
 centile for 
gestational age and appropriate growth for gestational age (AGA) was defined as birth 
weight centile above 10
th
 centile, according to both a contemporary Spanish reference 
normograms
18
 and a current local customized curve calculator.
19
. Only newborns with 
concordance of classification (AGA/SGA) by both birth weight curves were included. 
Patient´s selection was performed randomly in a 1:1 ratio of SGA and AGA of G1. 
Exclusion criteria were multiple pregnancies, aneuploidy or genetic syndrome, major 




Current contact data could be retrieved from 1,165 offspring’s (G1) that fulfilled 
inclusion criteria. A total of 623 G1 individuals -now adults- agreed to participate in the 
study after an invitation letter and a phone call. From those, 152 individuals reported to 
have at least one offspring (G2) and an oral questionnaire was applied to obtain 
information about pregnancy characteristics of their offspring. 
The study was approved by the Ethical Committees of Hospital Sant Joan de 
Deu (Registry N° PIC-101-14) and Hospital Clinic (Registry N° HCB/2014/0598). All 
patients included signed a written informed consent. 
Definitions and variables 










For current study, the following definitions were used: The term generation 0 
(G0) was applied to the mother of the index patient. Generation 1 (G1) was applied to 
the index patient, born between 1975 and 1993, and contacted as an adult. Generation 2 
(G2) was applied to the offspring of G1, born between 2005 and 2015 (Figure 1). 
The main exposure variable was defined as the presence of SGA in G1. The 
primary outcome was considered as the presence of SGA in G2. The presence of any 
placental disease (SGA, preeclampsia, gestational hypertension and/or placental 
abruption) was considered as a secondary outcome. SGA was defined as birth weight 
below 10
th
 percentile according to local reference curves,
18,19
 for G1, and current 
customized curves for G2.
19
 Preeclampsia was defined as the presence of hypertension 
and proteinuria after 20 weeks of pregnancy in a previously normotensive patient. 
Hypertension was considered as at least two measurements with systolic blood pressure 
≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, with 6 hours apart. 




Sample size estimation 
For sample-size calculation, the freely available software OpenEpi, with 
corrected Fleiss method, was used. Based on a hypothetical 30% incidence of SGA in 
exposed G2 offspring and a 10% incidence of SGA in unexposed group, with a 5% two-
sided alpha-error and with a power of 80%, a total of 143 patients were estimated to be 
needed. 
Statistical analysis 
Study groups were described and compared using mean ± standard deviation, 
median (interquartile range) or relative frequencies with corresponding t-test, Mann-












 tests or Fisher´s exact test when appropriated. Multiple logistic 
regressions were applied to adjust for potential confounders including gender, perinatal 
characteristics, sociodemographic data, cardiovascular risk factors (life style and 
chronic status) and anthropometry of G1. The analysis was performed by combining 
both first and second offspring (G2-any offspring) and stratified by offspring position. 
When both pregnancies were analysed, robust standard errors were obtained to account 
for non-independency (pregnancies are clustered within mothers). Additionally, an 
exploratory analysis was performed to evaluate the effect of parental gender on 
placental mediated disease. For all statistical analyses, STATA 14.2 (Statacorp, Texas 
USA) was used. A p-value less than 0.05 was considered as significant. 
  











Maternal and pregnancy characteristics of G0 
Pregnancy and perinatal characteristics of G0 pregnancies when delivering G1 
are described in Table 1. G0-pregnant women that delivered a SGA offspring were 
characterized by a lower maternal height and body surface area, with no difference in 
body mass index. In addition, these patients showed a higher rate of smoking during 
pregnancy, compared to patients that delivered a normal birth weight offspring. As 
expected, G1-SGA showed lower birth weight, birth weight percentile and placental 
weight than G1-AGA. There was a non-significant trend to higher rate of preeclampsia 
and cesarean section in G0-SGA as compared to G0-AGA. Gestational age at delivery 
was similar among groups. 
Current adult demographic and medical characteristics of G1 
G1-SGA as adults were characterized by a lower educational level, lower salary 
and higher tobacco use than G1-AGA (Table 2). Current anthropometric analyses 
showed that G1-SGA adults were shorter and lighter than G1-AGA, with no differences 
in gender, age, personal or familiar history of cardiovascular diseases. 
Perinatal outcomes of G2 
 Regarding G2 population, birth weight and birth weight percentile was lower 
when a parental background of SGA was present (Figure 2), with also a higher rate of 
preeclampsia and placental-mediated disease (Table 3). Although these differences were 
observed both in first and second offspring, changes were more evident in the first 
offspring (Table 3). The adjusted odds ratio for SGA and placental-mediated disease in 
the subsequent pregnancy was 2.79 and 3.15 respectively (Table 4).  










A stratified analysis according to G1 gender demonstrated a stronger 
transgenerational effect among G1-females: G2 birth weight was lower (Figure 3) and 
rate of placental-mediated disease higher (Figure 4) in G1-SGA females as compared to 
G1-SGA males. Among G1-females, the incidence of SGA in any G2 offspring was 
21.9% and 48.7% for G1-AGA and G1-SGA, respectively (p=0.02). This trend was 
similar for both, first and second pregnancy. Among G1-male parents, the incidence of 
SGA in any G2 offspring was 12.5% and 30.3% for G1-AGA and G1-SGA, 
respectively (p=0.048). 
  











Our study supports the transgenerational transmission of SGA and placental 
mediated diseases in a contemporary population. This transmission occurs both in the 
first and second offspring and seems to be stronger through the maternal lineage. 
Our data provide evidence suggesting a transgenerational transmission of SGA 
in the subsequent generation using a contemporary Mediterranean population. SGA 
background increased the risk of having a SGA offspring in almost three times, even 
after adjustment for confounders. Interestingly, the risk of developing any placental-
mediated disease (including SGA or maternal pregnancy-induced hypertension) in the 
following generation was also increased more than three times. These results are in line 
with most recent studies describing the transmission of low birth weight and SGA into 
the following generation.
14,21–23
 Castrillio et al  demonstrated an adjusted risk for SGA 
transmission of 2.1 (2.0 – 2.2) and 1.5 (1.5 – 1.6) for white and African-American 
women, respectively.
21
 Wikström et al reported that SGA mothers have also an 
increased risk of developing early preeclampsia (aOR=1.87; 95% CI= 1.38 – 2.35) and 
placental abruption (aOR=1.60; 95% CI= 1.23 – 2.09), with a non-significant impact on 
spontaneous preterm delivery or stillbirth.
23
 Selling et al, also reported a two-fold 
increased risk of delivering a SGA offspring if the mother was SGA at birth (OR= 2.68; 
95% CI= 2.11 – 3.41). However, a background of spontaneous preterm delivery did not 
increase the risk of SGA in the following generation.
21,22
 Indeed, our data also suggest 
no effect of gestational age at delivery on SGA transmission. Overall, most recent data 
suggest a 2 to 3-fold increase of SGA or placental related diseases in the subsequent 
population. However, data from the Dutch Famine cohort failed to demonstrate a 
transgenerational effect on birth weight or cardiovascular diseases.
24
 This discordance 
could be explained by relevant differences in the populations regarding main factors 










contributing to fetal smallness -mainly related to low maternal intake of nutrients- and 
timing -Dutch Famine occurring in the 40s-.  
Interestingly, our data further suggest a differential impact of parental gender on 
the transmission of SGA in offspring. Female SGA parents are associated with almost 
two-times higher rates of SGA as compared with male SGA parents. These results are in 
agreement with previous publications also suggesting a stronger maternal linkage effect. 
Coutinho et al demonstrated a greater impact of maternal birth weight rather than 
paternal birth weight, in both white and African-American population.
14
 In the same 
line, Skjærven et al showed that daughters of preeclamptic mothers demonstrated a two-
fold higher risk of developing preeclampsia compared to son´s partners pregnancies.
13
 
These findings are in line with experimental data suggesting that placental mediated 
diseases (mainly SGA and PE) are associated with genetic or epigenetic modifications 
that can be transmitted to the following generations via maternal germ-cell line, an 
altered in-utero environment or by maternal mitochondrial DNA.
10,15,25
  
In addition, to our knowledge, our study is the first to report a transmission of 
the transgenerational effect of SGA in the first and subsequent offspring of the same 
G2-generation, with a stronger association in the former. Regarding preeclampsia, again 
both first and subsequent offspring presented a higher risk, although first child 
accumulated a greater risk as compared to the second one. However, the rate of 
preeclampsia decreased from the first offspring to the second. This reduction in rate of 
PE in the second G2-offspring could be explained by the immunologic tolerance theory 
based on the observed higher risk of preeclampsia in a first pregnancy or after change of 
the male partner.
28
 It has been postulated that long-term exposure to paternal seminal 
plasma tolerizes the woman to male alloantigens, reducing the risk of an altered 
immunologic tolerance during the placentation process, allowing an adequate 










trophoblast implantation, and therefore, reducing the risk of PE in the current 
pregnancy.  
The present study has some strengths and limitations that merit comment. The 
main strength is the use of a well-phenotyped contemporary population with detailed 
maternal and pregnancy data from G0 and G1. Our database was constructed by an 
extensive review of medical charts and delivery registries in a single institution. This 
strategy allowed us to obtain very accurate data regarding perinatal outcomes. We 
acknowledge several limitations. Firstly, the diagnosis of SGA was based on birth 
weight centile as data on feto-placental ultrasound was not available on G1. Secondly, 
first trimester ultrasound in G0 pregnancy was not available to estimate gestational age, 
then patients with a doubtful last menstrual period at first obstetric control were 
excluded to minimize the inaccuracy in dating. In addition, maternal height and weight 
could not be used to customize the size of fetuses and newborns. Cases and controls 
were randomly selected and not paired by demographical characteristics such as 
educational level or smoking habits. However, logistic regressions were applied to 
adjust for potential confounders such as gender, perinatal characteristics, 
sociodemographic data, cardiovascular risk factors and anthropometry of G1. Finally, 
the non-significant trend of lower birthweight in G2-offspring of male parents could be 
related to an underpowered sample size for sub-analysis of parental gender. 
The clinical relevance of the present study resides in the impact of growth 
restriction not only on the affected individual but also on the future generations, 
offering a unique window of opportunity to improve health and prevent long-term 
consequences. From a public health perspective, the transgenerational evidence 
reinforce the importance and high value of strategies preventing or treating intrauterine 
growth restriction for improving the health of present and future generations. 
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Table 1. Maternal and perinatal characteristics of Generation 0 (G0) according to SGA 






G0 Maternal pre-pregnancy characteristics 
Age, years 27 (24 – 30) 25 (22 – 28) 0.01 
Low socio-economic status 3 (3.8) 8 (11.1) 0.08 
University education 8 (10.3) 6 (8.3) 0.7 
Height, m 1.59 ± 0.05 1.55 ± 0.06 0.0001 
Weight, kg 56 (53 – 62) 54 (50 – 59.5) 0.1 
Body mass index, kg/m2  22.8 (20.8 – 24.4) 22.2 (20.4 – 24.3) 0.7 
Smoking habit 2 (2.5) 9 (12.5) 0.02 
Chronic hypertension 2 (2.5) 2 (2.8) 0.9 
Diabetes Mellitus 0 1 (1.4) 0.3 
G0 Pregnancy characteristics    
Nulliparity 31 (40.8) 51 (70.8) <0.0001 
Gestational diabetes 0 0 NA 
Preeclampsia 1 (1.3) 2 (2.8) 0.5 
Gestational hypertension 0 2 (2.8) 0.1 
G0 Perinatal characteristics    
Induction of labor 3 (4.0) 6 (8.3) 0.5 
Labor – delivery interval, min 260 (190 – 355) 320 (230 – 420) 0.2 
Gestational age at birth, weeks 40.0 (39.0 – 40.9) 40.2 (39.3 – 41.1) 0.2 
Cesarean section 6 (8.2) 11 (15.3) 0.19 
Placental weight, g 600 (530 – 660) 470 (430 – 512) <0.0001 
Birthweight of G1, g 3,400 (3,190 – 3,525) 2,625 (2,445 – 2,710) <0.0001 
Birthweight percentile of G1 52.9 ± 18.9 3.4 ± 2.4 <0.0001 
Male gender of G1 48 (60.0) 33 (45.8) 0.08 
AGA= adequate for gestational age; SGA= small for gestational age. 
Continuous variables expressed as mean ± standard deviation or median (interquartile range). Categorical 
variables expressed as n (%). 
* p-value from chi2 or Fisher´s exact test was used to compare proportions, t-student to compare means 
and Mann-Whitney U to compare medians 
 
 










Table 2. Current adult demographic and medical characteristics of Generation 1 (G1) 







Male gender, % 46 (57.5) 32 (44.4) 0.11 
Age, years 35.5 (33.0 – 37.4) 34.7 (32.2 – 37.4) 0.39 
Low socio-economic status*, %  4 (5.6) 10 (15.6) 0.09 
University education, % 47 (58.8) 18 (25) <0.001 
Height, m  1.71 ± 0.08 1.63 ± 0.09 <0.001 
Weight, kg 73.6 (62.2 – 84.5) 65.9 (56.9 – 79.7) 0.047 
Body mass index, kg/m
2
 24.9 (22.1 – 26.9) 24.6 (21.7 – 28.7) 0.78 
Smoking habit, % 20 (25) 29 (40.3) 0.04 
Sedentarism, % 9 (12) 16 (24.2) 0.07 
AGA= appropriate growth for gestational age; SGA= small for gestational age. 
*Monthly income ≤ 750 euros. 
Categorical data expressed as n (%). Continuous data expressed as mean ± standard 
deviation or median (interquartile range). 
** p-value from chi2 or Fisher´s exact test was used to compare proportions, t-student 
to compare means and Mann-Whitney U to compare medians 
 
  










Table 3. Perinatal characteristics of Generation 2 (G2), according to SGA status in 







Any offspring    
   Gestational age at birth, weeks 39.5 (38 – 40) 40 (38 – 40) 0.001 
   Birthweight, g 3200 (2900 – 3500) 2950 (2680 – 3275) 0.51 
   Birthweight percentile 43 (19 – 75) 26 (7 – 52) <0.001 
   Small for gestational age, % 13 (16.3) 29 (40.3) 0.001 
   Preeclampsia or GH, % 1 (1.25) 7 (9.72) 0.03 
   Placental mediated disease*, % 14 (17.5) 31 (43.1) 0.001 
First offspring    
   Gestational age at birth, weeks 39.5 (38 – 40) 40 (38 – 40) 0.5 
   Birthweight, g 3200 (2830 – 3465) 2950 (2570 – 3288) 0.009 
   Birthweight percentile 38 (19 – 65) 18 (5 – 50) 0.004 
   Small for gestational age, % 10 (13.0) 24 (34.8) 0.02 
   Preeclampsia or GH, % 1 (1.25) 6 (8.3) 0.05 
   Placental mediated disease*, % 11 (12.6) 25 (33.3) 0.002 
Second offspring    
   Gestational age at birth, weeks 39.5 (38 – 40) 40 (38 – 40) 0.89 
   Birthweight, g 3291 ± 87.1 3048 ± 88.2 0.05 
   Birthweight percentile 70 (22 – 90) 27.5 (7 – 55) 0.02 
   Small for gestational age, % 3 (10) 9 (28.1) 0.07 
   Preeclampsia or GH, % 0 1 (1.03) 0.33 
   Placental mediated disease*, % 3 (10) 10 (31.3) 0.04 
AGA= appropriate growth for gestational age; SGA= small for gestational age; GH= 
gestational hypertension. 
*Placental mediated disease defined as the presence of SGA, preeclampsia or placental 
abruption 
Categorical data expressed as n (%). Continuous data expressed as mean ± standard 
deviation or median (interquartile range). 
** p-value from chi2 or Fisher´s exact test was used to compare proportions, t-student 
to compare means and Mann-Whitney U to compare medians 
  










Table 4. Odds ratios (95% confidence interval) for small for gestational age and 
placental mediated diseases in a subsequent pregnancy. 






Small for gestational age 
   Odds Ratio 
 
3.47 (1.62 – 7.43) 
 
3.57 (1.56 – 8.18) 
 
3.52 (0.85 – 14.57) 
   Adjusted Odds Ratio* 2.79 (1.11 – 6.97) 2.90 (1.06 – 7.91) 2.80 (0.37 – 21.12) 
Placental-mediated diseases 
   Odds Ratio 
 
3.56 (1.69 – 7.50) 
 
3.33 (1.49 – 7.47) 
 
4.13 (1.09 – 15.69) 
   Adjusted Odds Ratio* 3.15 (1.26 – 7.91) 3.19 (1.14 – 8.94) 2.79 (0.60 – 12.95) 
*Adjusted Odds Ratio by G1 gender, salary, educational level, body surface area and smoking status, 
obtained by univariate and multiple logistic regression. 
  












Figure 1. Flowchart of recruitment. 
AGA= adequate for gestational age; SGA= small for gestational age; G0= generation 0; 
G1= generation 1; G2= generation 2. 
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Figure 2. First offspring´s birth weight from AGA and SGA parents. 
*p<0.01 
 
AGA= adequate for gestational age; SGA= small for gestational age. 
  











Figure 3. First offspring´s birth weight from AGA and SGA parents, according to 
parental gender. 
*p<0.005. 















Figure 4. Rate of placental mediated diseases based on parental gender and SGA status 
of G1. 
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